A randomized prospective study to determine the effectiveness and safety of Eviprostat to treat chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)in comparison with pollen extract

A randomized prospective study to determine the effectiveness and safety of Eviprostat to treat chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)in comparison with pollen extract - A randomized prospective study to determine the effectiveness and safety of Eviprostat to treat chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)in comparison with pollen extract

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019618

Enrollment

100

Registered

2015-11-03

Start date

2009-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)

Interventions

Eviprostat (two capsules, q 8 h) for 8 weeks pollen extract(two capsules, q 8 h) for 8 weeks

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Inclusion criteria were (1) men between 20 and 80 year of age with symptoms of pelvic pain for 3 months or more before study (2) Patients with a total National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score > 15 point (3) Patients diagnosed with NIH category IIIA and IIIB using the PPMT (pre- and post-massage test) .

Exclusion criteria

Exclusion criteria: (1) documented urinary tract infection (midstream urine culture with at least 100,000 colony-forming units per milliliter), (2) history of urethritis, epididymitis or sexually transmitted disease (STD) (3) history of prostate surgery (4)history of urogenital cancer (5) treatment with phytotherapeutic agents, a-blocker agents, or antimicrobials.

Design outcomes

Primary

Measure	Time frame
Participants were evaluated using the NIH-CPSI and the International Prostate Symptom Score (IPSS) at baseline and after 4 and 8 weeks.	—

Countries

Japan

Contacts

Public ContactYasuhiro Hashimoto

Hirosaki University Urology

bikkuri@opal.plala.or.jp0172-33-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026